Floatz logo

Polatuzumab Vedotin

Indolent B-Cell Non-Hodgkin Lymphoma

University of Washingtonantibody_drug_conjugatePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

39 Active assets in the Indolent B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Fox Chase Cancer Center
Phase 3BB
Pembrolizumab
University of Washington
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
German High-Grade Non-Hodgkin's Lymphoma Study Group
Phase 3BB

View all 50 →

Same molecule, other indications

Polatuzumab Vedotin is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Large B-Cell Lymphoma (LBCL)Dormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →